207 related articles for article (PubMed ID: 38253803)
1. The Molecular Twin artificial-intelligence platform integrates multi-omic data to predict outcomes for pancreatic adenocarcinoma patients.
Osipov A; Nikolic O; Gertych A; Parker S; Hendifar A; Singh P; Filippova D; Dagliyan G; Ferrone CR; Zheng L; Moore JH; Tourtellotte W; Van Eyk JE; Theodorescu D
Nat Cancer; 2024 Feb; 5(2):299-314. PubMed ID: 38253803
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in artificial intelligence for pancreatic ductal adenocarcinoma.
Hayashi H; Uemura N; Matsumura K; Zhao L; Sato H; Shiraishi Y; Yamashita YI; Baba H
World J Gastroenterol; 2021 Nov; 27(43):7480-7496. PubMed ID: 34887644
[TBL] [Abstract][Full Text] [Related]
3. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.
Qian ZR; Rubinson DA; Nowak JA; Morales-Oyarvide V; Dunne RF; Kozak MM; Welch MW; Brais LK; Da Silva A; Li T; Li W; Masuda A; Yang J; Shi Y; Gu M; Masugi Y; Bui J; Zellers CL; Yuan C; Babic A; Khalaf N; Aguirre A; Ng K; Miksad RA; Bullock AJ; Chang DT; Tseng JF; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Thorner AR; Ducar M; Wollison B; Laing A; Hahn WC; Meyerson M; Fuchs CS; Ogino S; Hornick JL; Hezel AF; Koong AC; Wolpin BM
JAMA Oncol; 2018 Mar; 4(3):e173420. PubMed ID: 29098284
[TBL] [Abstract][Full Text] [Related]
4. Machine Learning of Histopathological Images Predicts Recurrences of Resected Pancreatic Ductal Adenocarcinoma With Adjuvant Treatment.
Yamaguchi R; Morikawa H; Akatsuka J; Numata Y; Noguchi A; Kokumai T; Ishida M; Mizuma M; Nakagawa K; Unno M; Miyake A; Tamiya G; Yamamoto Y; Furukawa T
Pancreas; 2024 Feb; 53(2):e199-e204. PubMed ID: 38127849
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of artificial intelligence for predicting recurrence following surgery for pancreatic cancer: Retrospective cohort study.
Lee KS; Jang JY; Yu YD; Heo JS; Han HS; Yoon YS; Kang CM; Hwang HK; Kang S
Int J Surg; 2021 Sep; 93():106050. PubMed ID: 34388677
[TBL] [Abstract][Full Text] [Related]
6. Artificial intelligence for assessment of vascular involvement and tumor resectability on CT in patients with pancreatic cancer.
Bereska JI; Janssen BV; Nio CY; Kop MPM; Kazemier G; Busch OR; Struik F; Marquering HA; Stoker J; Besselink MG; Verpalen IM;
Eur Radiol Exp; 2024 Feb; 8(1):18. PubMed ID: 38342782
[TBL] [Abstract][Full Text] [Related]
7. Artificial intelligence uses multi-omic data to predict pancreatic cancer outcomes.
Nat Cancer; 2024 Feb; 5(2):226-227. PubMed ID: 38279059
[No Abstract] [Full Text] [Related]
8. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study.
Nahm CB; Turchini J; Jamieson N; Moon E; Sioson L; Itchins M; Arena J; Colvin E; Howell VM; Pavlakis N; Clarke S; Samra JS; Gill AJ; Mittal A
Eur J Surg Oncol; 2019 Feb; 45(2):218-224. PubMed ID: 30348604
[TBL] [Abstract][Full Text] [Related]
9. Immunohistological evaluation of mismatch repair deficiency in pancreatic ductal adenocarcinoma treated with surgical resection.
Otsuka H; Murakami Y; Uemura K; Kondo N; Nakagawa N; Okada K; Seo S; Takahashi S
J Hepatobiliary Pancreat Sci; 2020 Jul; 27(7):421-428. PubMed ID: 32219999
[TBL] [Abstract][Full Text] [Related]
10. Performance comparison between multi-center histopathology datasets of a weakly-supervised deep learning model for pancreatic ductal adenocarcinoma detection.
Carrillo-Perez F; Ortuno FM; Börjesson A; Rojas I; Herrera LJ
Cancer Imaging; 2023 Jun; 23(1):66. PubMed ID: 37365659
[TBL] [Abstract][Full Text] [Related]
11. Artificial Intelligence to Predict Lymph Node Metastasis at CT in Pancreatic Ductal Adenocarcinoma.
Bian Y; Zheng Z; Fang X; Jiang H; Zhu M; Yu J; Zhao H; Zhang L; Yao J; Lu L; Lu J; Shao C
Radiology; 2023 Jan; 306(1):160-169. PubMed ID: 36066369
[TBL] [Abstract][Full Text] [Related]
12. Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities.
Wang Y; Lakoma A; Zogopoulos G
Genes (Basel); 2020 Sep; 11(9):. PubMed ID: 32967105
[TBL] [Abstract][Full Text] [Related]
13. Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma.
Franko J; Krasinskas AM; Nikiforova MN; Zarnescu NO; Lee KK; Hughes SJ; Bartlett DL; Zeh HJ; Moser AJ
J Gastrointest Surg; 2008 Oct; 12(10):1664-72; discussion 1672-3. PubMed ID: 18677542
[TBL] [Abstract][Full Text] [Related]
14. Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma.
Hu H; Zhu Y; Pu N; Burkhart RA; Burns W; Laheru D; Zheng L; He J; Goggins MG; Yu J
J Am Coll Surg; 2020 Nov; 231(5):527-535.e14. PubMed ID: 32659497
[TBL] [Abstract][Full Text] [Related]
15. Molecular advances in pancreatic cancer: A genomic, proteomic and metabolomic approach.
Rajesh S; Cox MJ; Runau F
World J Gastroenterol; 2021 Aug; 27(31):5171-5180. PubMed ID: 34497442
[TBL] [Abstract][Full Text] [Related]
16. A personalized approach to pancreatic ductal adenocarcinoma and its application in surgical practice.
Schizas D; Koumpoura A; Galari M; Economopoulou P; Vailas M; Sotiropoulou M; Dimitroulis D; Maroulis I; Felekouras E
Per Med; 2021 Sep; 18(6):613-627. PubMed ID: 34676789
[TBL] [Abstract][Full Text] [Related]
17. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions.
du Rieu MC; Torrisani J; Selves J; Al Saati T; Souque A; Dufresne M; Tsongalis GJ; Suriawinata AA; Carrère N; Buscail L; Cordelier P
Clin Chem; 2010 Apr; 56(4):603-12. PubMed ID: 20093556
[TBL] [Abstract][Full Text] [Related]
19. Multiomics, artificial intelligence, and precision medicine in perinatology.
Pammi M; Aghaeepour N; Neu J
Pediatr Res; 2023 Jan; 93(2):308-315. PubMed ID: 35804156
[TBL] [Abstract][Full Text] [Related]
20. FASN multi-omic characterization reveals metabolic heterogeneity in pancreatic and prostate adenocarcinoma.
Chianese U; Papulino C; Ali A; Ciardiello F; Cappabianca S; Altucci L; Carafa V; Benedetti R
J Transl Med; 2023 Jan; 21(1):32. PubMed ID: 36650542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
